ONWARD Awarded Nine New Patents in Collaboration with Caltech, UCLA, EPFL, and University of Louisville
6.1.2022 09:00:00 EET | Business Wire | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the company and its partners have been awarded nine new patents, seven of them in collaboration with leading neuroscience research laboratories at Caltech, UCLA, EPFL, and University of Louisville.
The patents cover a broad range of technologies and activities encompassing ONWARD’s implantable and external technology platforms, ARCIM and ARCEX, and protecting key elements of those systems such as lead designs, spinal cord stimulation paradigms, closed-loop control systems and machine learning algorithms. The patents were awarded in the US, France, Canada, and Germany.
“Our many exclusive IP license agreements with the world’s top neuroscience research universities continue to bear fruit, adding to an already impressive IP portfolio of over 300 issued or pending patents”, said Dave Marver, Chief Executive Officer of ONWARD. “We are taking full advantage of our first-mover position to secure seminal and strategic intellectual property borne from our own engineering labs or prosecuted in collaboration with others.”
The Company has IP licensing arrangements in place with Caltech, EPFL, UCLA, University of Louisville, University of Minnesota, Univesity of British Columbia and University of Calgary.
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.
About ONWARD
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005853/en/
Contact information
For Company Enquiries:
ONWARD
info@onwd.com
For Media and Investor Enquiries:
Backstage Communication
Gunther De Backer
Tel: +32 (0)475 903 909
gunther@backstagecom.be
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The UAE’s Higher Colleges of Technology Celebrates Record Graduating Cohort of More Than 6,70010.11.2026 14:18:00 EET | Press release
Higher Colleges of Technology (HCT) – one of the largest applied higher education institutions in the region – has celebrated its biggest graduating cohort to date, with more than 6,700 graduates from the 2025-2026 academic year, with the graduating cohort some 43% larger than the previous year’s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110846231/en/ More than 12,000 people attended HCT’s biggest graduating cohort to date (Photo: AETOSWire) More than 12,000 people gathered at Etihad Arena in Abu Dhabi for the ceremony, held under the theme “Strong Roots. Lasting Impact.”, in the presence of His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence and founder of HCT. Also attending were His Excellency Dr Ahmad Belhoul Al Falasi, UAE Minister of Sports and Chancellor of HCT; Dr Faisal Alayyan, HCT President and CEO; senior government officials, institutional leaders, faculty, alum
Component Sense Celebrates 25 Years With Over 80 Million Electronic Components Saved From Landfill10.11.2026 14:00:00 EET | Press release
Component Sense, a global company specialising in the redistribution of excess and obsolete electronic components, has now saved over 80 million components from landfill. The milestone coincides with its 25th anniversary this November, which it is marking by planting 2,500 trees with One Tree Planted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110298637/en/ Kenny McGee, CEO and Founder, Component Sense The company redistributes excess components from Tier 1 original equipment manufacturers (OEMs) and electronics manufacturing services (EMS) providers to a global network of buyers, helping manufacturers recoup value from inventory that would otherwise go to waste. Excess inventory is both a financial and an environmental burden for electronics manufacturers. With lead times still running long, shortages and surpluses exist side by side. Parts sit unused in one manufacturer’s warehouse, tying up capital, while another s
FDA Approves Promega OncoMate ® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA ® in MSI-High Solid Tumors10.11.2026 14:00:00 EET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System designed to identify patients with microsatellite high (MSI-H) solid tumors as a companion diagnostic designed for KEYTRUDA®, Merck’s (known as MSD outside the U.S. and Canada) anti-PD-1 therapy. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in solid tumor tissue. MSI status can be used to inform treatment decisions and support precision oncology strategies. “This approval reflects our dedication to providing meaningful diagnostic advances, developed to the highest quality and regulatory standards,” says Alok Sharma, Global Clinical Market Director at Promega. “Our test connects patients with the therapy most likely to help them, working alongside our pharmaceutical collaborators and the clinicians who use the result.” This approval was supported through a collaboration with Merck, which markets KEYTRUDA®. Together, the companies are working to a
Suzano Publishes First Report Aligned With Taskforce on Nature-related Financial Disclosures Recommendations10.11.2026 13:18:00 EET | Press release
Suzano, the world’s largest pulp producer, has published its first report aligned with the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD). The TNFD reporting framework helps organizations identify and assess how their dependencies and impacts may generate nature and biodiversity related risks and opportunities, and to disclose how they are integrated into the company’s governance, strategy, and corporate management. Initially focused on Suzano’s direct Brazilian operations, the report establishes methodological foundations, strengthens internal capabilities, and creates a pathway for the gradual expansion of nature-related assessments and disclosures over the coming years. The report also reinforces Suzano’s Nature Strategy, launched in November 2025. As part of its ongoing commitment to stronger management and greater transparency regarding ecosystem-related issues, Suzano has refined its methodology for identifying ‘Sensitive Locations’ by combining p
Robbyant Releases LingBot-Touch to Bring General-Purpose Touch Perception to Robots10.11.2026 11:23:00 EET | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-Touch, a tactile foundation model that gives robots a critical missing sense by enabling robust touch perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109284905/en/ LingBot-Touch encodes magnetic tactile, visual tactile, and piezoresistive signals into unified tactile tokens for use by different action models. Pre-trained on nearly 5,000 hours of real-world tactile data, the model covers three mainstream sensing modalities—magnetic tactile, visual tactile, and piezoresistive sensing—and translates their diverse signals into a unified tactile representation. This allows different dexterous hands and action models to share and reuse tactile understanding, enabling robots to not only “see clearer” and “think deeper,” but also “feel sharper” during fine manipulation tasks, such as turning pages, unscrewing bottle ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom